01—Abstract
Summary
Summary of the 8-K filed June 27, 2024. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation (Nasdaq: UTHR) reported on its June 27, 2024 Form 8-K that shareholders approved, at the 2024 Annual Meeting held June 26, 2024, an amendment and restatement of its Amended and Restated 2015 Stock Incentive Plan.
The 2024 Restatement increases the maximum number of shares issuable under the Plan by 1,320,000 shares, extends the Plan's expiration date to April 25, 2034, revises minimum vesting provisions to permit certain exceptions, and revises the limit on non-employee director compensation to address certain special assignments. The plan amendment was approved by shareholders with 32,982,705 votes for and 4,663,248 votes against. At the same meeting, shareholders elected all eleven director nominees to one-year terms, approved an advisory resolution on executive compensation (35,662,995 for, 1,974,530 against), and ratified Ernst & Young LLP as the independent registered public accounting firm for 2024 (37,189,791 for, 1,373,453 against).
Shareholders also elected Jan Malcolm, former Minnesota Commissioner of Health, to the Board, filling the seat vacated by Professor Katherine Klein, who did not stand for re-election. The company announced Malcolm's election in a press release furnished as Exhibit 99.1. The filing is largely governance-related, with the most investor-relevant items being the expanded equity incentive pool and the extended plan term, alongside a board refresh the company describes as focused on new skill sets for its public benefit purpose and organ manufacturing programs.
02—Key points
Key Highlights
- Shareholders approved the 2024 Restatement of the Amended and Restated 2015 Stock Incentive Plan, effective June 26, 2024, increasing the share reserve by 1,320,000 shares.
- The Plan's expiration date was extended to April 25, 2034.
- The Plan amendment received 32,982,705 votes for and 4,663,248 votes against, with 40,899 abstentions and 899,233 broker non-votes.
- Shareholders approved the advisory say-on-pay resolution with 35,662,995 votes for and 1,974,530 votes against.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for 2024 with 37,189,791 votes for and 1,373,453 votes against.
- Jan Malcolm, former Minnesota Commissioner of Health, was elected to the Board, filling the seat of Professor Katherine Klein, who did not stand for re-election.
- All eleven director nominees were elected to one-year terms, with Christopher Causey receiving the lowest vote count of support among those listed at 32,655,777 for.
03—Questions
Frequently Asked Questions
What changes were made to the stock incentive plan?
The 2024 Restatement increases the maximum number of shares that may be issued under the Plan by 1,320,000 shares, extends the Plan's expiration date to April 25, 2034, revises minimum vesting provisions to allow certain exceptions in line with best practices, and revises the limit on non-employee director compensation to address certain special assignments.
Did shareholders support the stock incentive plan amendment?
Shareholders approved the amendment and restatement, with 32,982,705 votes for, 4,663,248 votes against, 40,899 abstentions, and 899,233 broker non-votes.
Who joined the Board of Directors?
Jan Malcolm, former Minnesota Commissioner of Health, was elected by shareholders at the June 26, 2024 annual meeting. She filled the seat previously held by Professor Katherine Klein, who did not stand for re-election.
How did shareholders vote on executive compensation?
In an advisory resolution, shareholders approved executive compensation with 35,662,995 votes for, 1,974,530 votes against, 49,327 abstentions, and 899,233 broker non-votes.
Which auditor was ratified for 2024?
Shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024, with 37,189,791 votes for, 1,373,453 votes against, and 22,841 abstentions.
04—Continue